Skip to main content
Premium Trial:

Request an Annual Quote

Roche Extends Expiration of Tender Offer for Foundation Medicine Shares

NEW YORK(GenomeWeb) – Roche today said it has extended the expiration of its tender offer for common shares of Foundation Medicine to midnight EST at the end of the day April 6. 

The tender offer for 15,604,288 shares of Foundation's stock at $50 per share is part of a $1.2 billion stake that Roche plans to take in the Cambridge, Mass.-based cancer molecular diagnostics firm. All other terms and conditions of the tender offer remain the same.

As of March 1, about 7.7 million shares of Foundation had been tendered and not withdrawn, Roche said, adding that it does not anticipate a further extension of the tender offer.

The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.